Moreover, ETA exerted significant beneficial differences in glucose homeostasis, dyslipidemia, and liver function tests as well as significantly ameliorated NASH and even MS-associated early hepatic fibrosis via the attenuation of the NF-κB/TNF-α/TGF-β1 signaling pathway in the liver; this pathway was activated in HFHF-fed rats. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.